Tony Fimreite

Nordea Investment Management AB (Norway) (NIM Norway) is the investment management division of Nordea Investment Management AB, itself a subsidiary of financial group Nordea Bank AB (SSE: NDA, ADR: NRBAY) in Norway. Headquartered in Bergen, NIM Norway manages a range of Norwegian funds, including pension funds, primarily for institutions.

Viking Venture AS is a venture capital investment firm founded in 2001 by Erik Fjellvær Hagen and Jostein Vik and is headquartered in Trondheim, Norway.

Powel AS supplies software solutions to the energy, public, and contracting sectors. It develops software and associated services designed for power generators, distribution companies, and local authorities. The company was founded in 1996 and is headquartered in Trondheim, Norway.

GasSecure AS provides wireless optical gas detector and wireless communication for industrial applications. It offers detection solutions to the oil and gas industries. The firm manufactures wireless infrared gas detectors based on its proprietary Microelectromechanical System technology and holds a number of patents relating to its proprietary measurement technique. Its product GasSecure GS01 is a wireless hydrocarbon infrared gas detector installations range from arctic to tropical conditions and covers offshore platforms, terminals, tanks farms, drill sites, and petrochemical plants. The company was founded by Knut Bærøe Sandven and Håkon Sagberg in 2008 and is headquartered in Oslo, Norway.

Borea Asset Management AS (Borea) is the investment advisory subsidiary of Borea AS in Norway. Headquartered in Bergen, the firm was founded in 2005 and is owned by Trond Mohn, the Rieber, Ulstein family and employees. Borea manages alternative investment funds, mutual fund management, and provides active management and investment advice to large professional clients and wealthy private individuals.

Part of Norne Eierselskap AS, Norne Securities AS is a brokerage services provider. The company is based in Bergen, Norway. Erik Valen has been the CEO of the Norwegian company since 2014.

Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn.